 |
|
|
| |
Real World Experience with DAA Regimens - Phase 4 HCV TARGET Study
|
| |
| |
- Phase 4 Study: Sofosbuvir+Peg/Rbv, Sofosbuvir+Rbv, Simeprevir+sofosbuvir, Simeprevir+sofosbuvir+Rbv
Reported by Jules Levin
AASLD/EASL Special Conference on Hepatitis C
New York City, New York
September 12 - 13
David R Nelson MD
Assistant Vice President for Research
Professor of Medicine
Director, Clinical and Translational Science Institute
University of Florida
Gainesville, USA
|
| |
|
|
|
|
|
